The estimated Net Worth of Simba Gill is at least $167 Mille dollars as of 7 November 2023. Simba Gill owns over 1,172 units of Foghorn Therapeutics stock worth over $166,211 and over the last 7 years Simba sold FHTX stock worth over $460.
Simba has made over 6 trades of the Foghorn Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Simba exercised 1,172 units of FHTX stock worth $10,864 on 7 November 2023.
The largest trade Simba's ever made was exercising 82,000 units of Foghorn Therapeutics stock on 12 September 2022 worth over $59,860. On average, Simba trades about 7,430 units every 25 days since 2018. As of 7 November 2023 Simba still owns at least 17,930 units of Foghorn Therapeutics stock.
You can see the complete history of Simba Gill stock trades at the bottom of the page.
Simba's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over $262,160 worth of Foghorn Therapeutics stock and bought 305,500 units worth $4,888,000 . The most active insiders traders include Adam Koppel, Ian F Smith e B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of $663,343. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth $190,000.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: